Beta-blocker drugs serve a key role in the treatment of heart failure, preventing bombardment of the heart by catecholamines – substances like epinephrine and norepinephrine – which...
When the heart begins to fail, the body does everything in its power to fix the situation. But sometimes, those compensatory mechanisms ultimately do more harm than good. Such is the case with the...
Until she fainted in 2012, Alicia didn’t know she was sick. Feeling tired and out of breath were “normal for me,” says the now 52-year-old single mom. The Glenside resident believed she felt that way because she was overweight and out of shape. She was working 10- to 12-hours daily attending her daughter Shannon’s high school track meets and working part-time on an online MBA degree.
After suffering a seizure in 2000, Brain learned that a virus had destroyed the lower third of his heart. He received a defibrillator and a dual pacemaker. More than a decade later, his heart function began to deteriorate further. So his doctors in the Lehigh Valley recommended that Brian go to the Temple Heart & Vascular Institute—where, at the age of 70, he received a heart transplant in December 2013.
Just nine months after receiving a heart transplant at the Temple Heart and Vascular Institute, Jim, a professional actor, was back on stage—playing Daddy Warbucks in the musical “Annie.”
Over the last two decades, MCSDs have been developed to augment or supplant failing myocardial performance. This therapy has been used successfully as a bridge to heart transplantation, a bridge to recovery, and as permanent implantation or "destination therapy" for intractable heart failure. Although heart transplantation offers life-saving therapy for selected patients, its use is limited by a supply of donor organs that currently meets less than one-tenth the need. As a consequence, the number of MCSD implantations has increased in recent years.
The QP ExCELs study is designed to confirm safety and efficacy of the BIOTRONIK Sentus OTW QP left ventricular leads to satisfy FDA requirements for regulatory approval of the leads in the US. ...
The response to therapy with a fixed dose combination of isosorbide dinitrate and hydralazine (FDC I/H) is enhanced in African Americans with heart failure and reduced ejection fraction (HFrEF) when...
